Secondary analysis of the phase III GY004 trial (n=489, recurrent ovarian cancer): NFOSI-18 Total and DRS-P scales showed good reliability (α 0.72–0.87), moderate convergent validity and responsiveness; suggested change thresholds 4–12 (Total) and 3–8 points (DRS-P).
Secondary analysisn = 489
Tang et al. Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004